• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PhaseBio raises additional $23M in Series B financing

PhaseBio raises additional $23M in Series B financing

June 7, 2012
CenterWatch Staff

PhaseBio Pharmaceuticals, a Malvern, Penn.-based, privately-held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, has raised a total of $48.4 million from its Series B financing following receipt of the third tranche to advance the company's product development programs.

In December 2009, PhaseBio raised $25 million in a Series B financing led by New Enterprise Associates, with participation by OSI Investment Holdings (now Astellas Venture Management) and previous investors Johnson & Johnson Development, Hatteras Venture Partners and Fletcher Spaght Ventures. These investors have now provided an additional $23 million.

The funding will support PhaseBio's phase IIb clinical testing of Glymera for the treatment of type 2 diabetes; a phase I clinical study of Vasomera in patients with stage 1 and 2 essential hypertension and additional preclinical work to support further clinical development of Vasomera for the treatment of acute and chronic heart failure and pulmonary hypertension; and to complete a phase I/IIa clinical study of Insumera, a fully native mature insulin fused to ELP, for type 2 diabetes.

"This additional investment with participation by all of our investors reflects their confidence in the PhaseBio product development programs, our versatile ELP technology platform and the extraordinary progress we have made in advancing our pipeline," said Christopher Prior, Ph.D., CEO of PhaseBio. "This provides us great flexibility in continuing to grow the value of PhaseBio.”

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing